Lexicon (LXRX) grants RSUs and stock options to SVP Suma Gopinathan

Rhea-AI Filing Summary

Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.

The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gopinathan Suma

Role SVP, Discovery

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	238,450	$0.00	--
Grant/Award	Stock Option (Right to Buy)	357,680	$0.00	--

Holdings After Transaction: Restricted Stock Units — 238,450 shares (Direct); Stock Option (Right to Buy) — 357,680 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gopinathan Suma

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

THE WOODLANDS TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Discovery

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		238,450		(2)	(2)	Common Stock	238,450	$0	238,450	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		357,680		(3)	02/12/2036	Common Stock	357,680	$0	357,680	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Suma Gopinathan, M.S, Ph.D.	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LXRX report for Suma Gopinathan?

Lexicon Pharmaceuticals reported that SVP, Discovery Suma Gopinathan received equity awards. She was granted 238,450 restricted stock units and a stock option for 357,680 shares on February 12, 2026, as part of her compensation package.

How many restricted stock units were granted to the LXRX executive?

Suma Gopinathan received 238,450 restricted stock units. Each unit represents a contingent right to one share of Lexicon Pharmaceuticals common stock, aligning her interests with shareholders through time-based vesting over multiple years following the grant.

What are the vesting terms for Suma Gopinathan’s LXRX restricted stock units?

The restricted stock units vest in three equal installments. One-third of the 238,450 units vests on February 28 of each of the three years following the grant year, subject to her continued service with Lexicon Pharmaceuticals.

What stock option grant did LXRX award to Suma Gopinathan?

Lexicon Pharmaceuticals granted Suma Gopinathan a stock option for 357,680 shares. The option has an exercise price of $1.37 per share and gives her the right to buy company common stock if she meets the vesting conditions.

How does the LXRX stock option for Suma Gopinathan vest over time?

The option vests 25% of the 357,680 shares on the first anniversary of the February 12, 2026 grant. The remaining shares vest in equal monthly installments of 1/48th for each month of continued service until the February 12, 2036 expiration.

Is Suma Gopinathan’s Form 4 transaction a stock purchase or an award?

The Form 4 reflects equity awards, not an open-market stock purchase. It reports an acquisition of restricted stock units and stock options granted as compensation, both recorded with transaction code “A” for grant, award, or other acquisition.